- Home
- PEG vs TAK Comparison
PEG vs TAK Comparison
Compare PEG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEG | TAK |
|---|---|---|
| Founded | 1903 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PEG | TAK |
|---|---|---|
| Price | $80.40 | $17.45 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $90.58 | N/A |
| AVG Volume (30 Days) | 3.3M | ★ 3.4M |
| Earning Date | 02-24-2026 | 01-29-2026 |
| Dividend Yield | 3.06% | ★ 3.06% |
| EPS Growth | ★ 2.23 | N/A |
| EPS | ★ 4.16 | 0.45 |
| Revenue | $11,718,000,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $2.94 | $0.47 |
| P/E Ratio | ★ $19.79 | $38.34 |
| Revenue Growth | ★ 12.35 | N/A |
| 52 Week Low | $74.67 | $12.99 |
| 52 Week High | $91.26 | $17.26 |
Technical Indicators
Market Signals| Indicator | PEG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 74.99 |
| Support Level | $77.90 | $16.63 |
| Resistance Level | $82.48 | $17.26 |
| Average True Range (ATR) | 1.51 | 0.25 |
| MACD | 0.32 | 0.07 |
| Stochastic Oscillator | 53.27 | 94.33 |
Price Performance
Historical ComparisonAbout PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.